Spinal Muscular Atrophy (SMA) Pipeline Review 2020: Therapeutic Analysis Report Featuring 28 Companies & Drug Profiles - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Spinal Muscular Atrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 3, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 8 and 2 molecules, respectively.

Spinal Muscular Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Spinal Muscular Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (Central Nervous System)

Key Topics Covered:

Introduction

• Spinal Muscular Atrophy (SMA) - Overview
• Spinal Muscular Atrophy (SMA) - Therapeutics Development

Spinal Muscular Atrophy (SMA) - Therapeutics Assessment

Spinal Muscular Atrophy (SMA) - Companies Involved in Therapeutics Development

Spinal Muscular Atrophy (SMA) - Drug Profiles

Spinal Muscular Atrophy (SMA) - Dormant Projects

• Spinal Muscular Atrophy (SMA) - Discontinued Products
• Spinal Muscular Atrophy (SMA) - Product Development Milestones

Appendix

Companies Mentioned

• Allianz Pharmascience Ltd
• AlphaCognition Inc
• Anima Biotech Inc
• Armgo Pharma Inc
• AveXis Inc
• Biogen Inc
• Bioleaders Corp
• BioMarin Pharmaceutical Inc
• Biophytis SA
• Cell Tech Pharmed Co
• Enzerna Biosciences LLC
• Exicure Inc
• F. Hoffmann-La Roche Ltd
• Genea Biocells
• GNT Pharma Co Ltd
• Imago Pharmaceuticals Inc
• Kowa Co Ltd
• Neurotune AG
• Novartis AG
• Ono Pharmaceutical Co Ltd
• Ractigen Therapeutics Inc
• Reborna Biosciences Inc
• Sarepta Therapeutics Inc
• Scholar Rock Inc
• Shift Pharmaceuticals
• Spotlight Innovation Inc
• Vybion Inc
• Xcelthera INC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/23eecj